• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

帕西瑞肽成功控制侵袭性垂体腺瘤肿瘤体积：一种具有挑战性疾病的新前景。

Successful Volume Control of Invasive Pituitary Adenoma Tumor With Pasireotide: A New Horizon for a Challenging Disease.

作者信息

Elhadd Tarik, Ibrahim Shahd I, Abdelmahmuod Elabbass, Webb Susan M

机构信息

Pituitary Clinic, Endocrine Section, Department of Medicine, Hamad General Hospital, Hamad Medical Corporation, P.O. Box 3050, Doha, Qatar.

Department of Medicine, Univ Autonoma Barcelona, Research Center for Pituitary Diseases, Institut de Recerca Sant Pau (IIB-Sant Pau) and CIBERER Unit 747, ISCIII, Department of Endocrinology, Hospital S Pau, Barcelona 08025, Spain.

出版信息

JCEM Case Rep. 2025 Apr 18;3(6):luaf075. doi: 10.1210/jcemcr/luaf075. eCollection 2025 Jun.

DOI:10.1210/jcemcr/luaf075
PMID:40255441
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12007491/
Abstract

A 62-year-old Sudanese female was diagnosed with a nonfunctioning pituitary adenoma in 2006. Despite undergoing 3 transsphenoidal surgeries and radiotherapy, her tumor persisted, causing debilitating symptoms, including headaches and visual defects. As a last resort, she was treated with pasireotide, a second-generation somatostatin analog with a broader receptor affinity than first-generation drugs. Over 6 months, the tumor mass was stabilized, and her symptoms, including headaches, disappeared. This case demonstrates a potential new therapeutic possibility for treating resistant pituitary adenoma with pasireotide, offering hope for patients when traditional treatments fail.

摘要

一名62岁的苏丹女性于2006年被诊断为无功能垂体腺瘤。尽管接受了3次经蝶窦手术和放射治疗，她的肿瘤仍持续存在，导致了使人衰弱的症状，包括头痛和视力缺陷。作为最后的手段，她接受了帕瑞肽治疗，这是一种第二代生长抑素类似物，与第一代药物相比具有更广泛的受体亲和力。在6个月的时间里，肿瘤体积稳定下来，她的症状，包括头痛，都消失了。该病例证明了用帕瑞肽治疗耐药垂体腺瘤的一种潜在新治疗可能性，为传统治疗失败的患者带来了希望。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d5a8/12007491/69d4dfa93e60/luaf075f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d5a8/12007491/5f980261d72f/luaf075f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d5a8/12007491/aabea0f31d48/luaf075f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d5a8/12007491/78c160c32d4a/luaf075f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d5a8/12007491/c860997947b8/luaf075f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d5a8/12007491/69d4dfa93e60/luaf075f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d5a8/12007491/5f980261d72f/luaf075f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d5a8/12007491/aabea0f31d48/luaf075f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d5a8/12007491/78c160c32d4a/luaf075f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d5a8/12007491/c860997947b8/luaf075f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d5a8/12007491/69d4dfa93e60/luaf075f5.jpg

相似文献

1
Successful Volume Control of Invasive Pituitary Adenoma Tumor With Pasireotide: A New Horizon for a Challenging Disease.帕西瑞肽成功控制侵袭性垂体腺瘤肿瘤体积：一种具有挑战性疾病的新前景。
JCEM Case Rep. 2025 Apr 18;3(6):luaf075. doi: 10.1210/jcemcr/luaf075. eCollection 2025 Jun.
2
Rapid response of Nelson's syndrome to pasireotide in radiotherapy-naive patient.未接受过放疗的患者中尼尔森综合征对帕瑞肽的快速反应
Clin Diabetes Endocrinol. 2020 Nov 7;6(1):22. doi: 10.1186/s40842-020-00110-7.
3
Impact of preoperative pasireotide therapy on invasive octreotide-resistant acromegaly.术前帕瑞肽治疗对侵袭性奥曲肽抵抗性肢端肥大症的影响。
Endocr J. 2018 Oct 29;65(10):1061-1067. doi: 10.1507/endocrj.EJ17-0487. Epub 2018 Aug 4.
4
Case Report: Opposite Tumoral and Hormonal Responses to Low-dose Pasireotide in Cushing's Disease.病例报告：库欣病对低剂量培高利特的相反肿瘤和激素反应。
Endocr Metab Immune Disord Drug Targets. 2024;24(7):845-849. doi: 10.2174/0118715303260160231020070423.
5
Pasireotide: A potential therapeutic alternative for resistant prolactinoma.培高利特：一种抵抗性泌乳素瘤的潜在治疗选择。
Ann Endocrinol (Paris). 2019 Apr;80(2):84-88. doi: 10.1016/j.ando.2018.07.013. Epub 2018 Sep 25.
6
Efficacy and safety of long-acting pasireotide in patients with somatostatin-resistant acromegaly: a multicenter study.长效帕瑞肽治疗生长抑素受体不敏感型肢端肥大症的疗效和安全性：一项多中心研究。
Endocrine. 2018 Nov;62(2):448-455. doi: 10.1007/s12020-018-1690-5. Epub 2018 Jul 26.
7
Sustained improvements in plasma ACTH and clinical status in a patient with Nelson's syndrome treated with pasireotide LAR, a multireceptor somatostatin analog.培高利特长效微球治疗 Nelson 综合征患者的临床疗效和血浆 ACTH 水平的持续改善：一种多受体生长抑素类似物。
J Clin Endocrinol Metab. 2013 May;98(5):1803-7. doi: 10.1210/jc.2013-1497. Epub 2013 Mar 28.
8
AIP-mutated acromegaly resistant to first-generation somatostatin analogs: long-term control with pasireotide LAR in two patients.对第一代生长抑素类似物耐药的AIP突变型肢端肥大症：两名患者使用帕瑞肽长效注射剂的长期控制情况
Endocr Connect. 2019 Apr;8(4):367-377. doi: 10.1530/EC-19-0004.
9
Temozolomide and pasireotide treatment for aggressive pituitary adenoma: expertise at a tertiary care center.替莫唑胺和帕瑞肽治疗侵袭性垂体腺瘤：三级医疗中心的经验
J Neurooncol. 2015 Mar;122(1):189-96. doi: 10.1007/s11060-014-1702-0. Epub 2015 Jan 3.
10
Cushing's disease after surgical resection and radiation therapy for nonfunctioning pituitary adenoma.非功能性垂体腺瘤手术切除及放射治疗后发生库欣病。
Endocr Pract. 2002 Jul-Aug;8(4):292-5. doi: 10.4158/EP.8.4.292.

本文引用的文献

1
Rapid Resolution of Recalcitrant Headache With Pasireotide in an Adult Patient With Acromegaly.帕西瑞肽快速缓解一名成年肢端肥大症患者的顽固性头痛
JCEM Case Rep. 2024 Aug 9;2(8):luae142. doi: 10.1210/jcemcr/luae142. eCollection 2024 Aug.
2
Update on Current Evidence for the Diagnosis and Management of Nonfunctioning Pituitary Neuroendocrine Tumors.非功能性垂体神经内分泌肿瘤的诊断和治疗的最新证据更新。
Endocrinol Metab (Seoul). 2023 Dec;38(6):631-654. doi: 10.3803/EnM.2023.1838. Epub 2023 Nov 15.
3
Efficacy and safety of temozolomide in the treatment of aggressive pituitary neuroendocrine tumours in Spain.
替莫唑胺治疗西班牙侵袭性垂体神经内分泌肿瘤的疗效和安全性。
Front Endocrinol (Lausanne). 2023 Aug 31;14:1204206. doi: 10.3389/fendo.2023.1204206. eCollection 2023.
4
Natural History of Non-Functioning Pituitary Adenomas: A Systematic Review and Meta-Analysis.无功能性垂体腺瘤的自然病程：系统评价和荟萃分析。
Horm Metab Res. 2023 Jul;55(7):443-451. doi: 10.1055/a-2096-1340. Epub 2023 Jul 10.
5
Gender-Specific Efficacy Revealed by Head-to-Head Comparison of Pasireotide and Octreotide in a Representative In Vivo Model of Nonfunctioning Pituitary Tumors.在无功能垂体瘤代表性体内模型中，帕西瑞肽与奥曲肽头对头比较所揭示的性别特异性疗效。
Cancers (Basel). 2021 Jun 21;13(12):3097. doi: 10.3390/cancers13123097.
6
Pituitary Adenomas: From Diagnosis to Therapeutics.垂体腺瘤：从诊断到治疗
Biomedicines. 2021 Apr 30;9(5):494. doi: 10.3390/biomedicines9050494.
7
The natural history and treatment of non-functioning pituitary adenomas (non-functioning PitNETs).无功能性垂体腺瘤（无功能性垂体腺瘤）的自然病史和治疗。
Endocr Relat Cancer. 2020 Oct;27(10):R375-R390. doi: 10.1530/ERC-20-0136.
8
Somatostatin Analogs in Clinical Practice: a Review.生长抑素类似物在临床实践中的应用：综述。
Int J Mol Sci. 2020 Feb 29;21(5):1682. doi: 10.3390/ijms21051682.
9
An aggressive functioning pituitary adenoma treated with peptide receptor radionuclide therapy.一例采用肽受体放射性核素治疗的侵袭性垂体功能腺瘤。
Eur J Nucl Med Mol Imaging. 2020 Apr;47(4):1015-1016. doi: 10.1007/s00259-019-04578-z. Epub 2019 Nov 18.
10
A Somatostatin Receptor Subtype-3 (SST) Peptide Agonist Shows Antitumor Effects in Experimental Models of Nonfunctioning Pituitary Tumors.生长抑素受体亚型 3（SST）肽激动剂在无功能性垂体瘤实验模型中显示出抗肿瘤作用。
Clin Cancer Res. 2020 Feb 15;26(4):957-969. doi: 10.1158/1078-0432.CCR-19-2154. Epub 2019 Oct 17.